Nektar Therapeutics (NKTR) Announces UCB's Cimzia Approved by U.S. FDA for Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Tweet Send to a Friend
Nektar Therapeutics (Nasdaq: NKTR) confirmed UCB's announcement that the US Food and Drug Administration (FDA) has approved Cimzia(R) (certolizumab pegol) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
